1 Min Read
Oct 7 (Reuters) - Rigel Pharmaceuticals Inc
* Expects to file an investigational new drug application (IND) with FDA for its first IRAK inhibitor in 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.